Hudson P J
CRC for Diagnostic Technologies and CSIRO Molecular Science, Parkville, Victoria, Australia.
Curr Opin Biotechnol. 1998 Aug;9(4):395-402. doi: 10.1016/s0958-1669(98)80014-1.
Recombinant antibodies and their fragments now represent over 30% of all biological proteins undergoing clinical trials, which recently culminated in FDA approval for the first engineered cancer therapeutic antibody. Other successful applications include both the effective enhancement of the human immune response for cancer therapy and the reduction of unwanted immune rejections following transplantation and antibody therapy. Important advances have been made in the methods for design, selection and production of these new types of engineered antibodies. Innovative selection methods have enabled the isolation of catalytic antibodies and high-affinity viral-specific antibodies, the latter capable of redirecting viruses for gene therapy applications. In numerous practical applications, recombinant antibody fragments have been fused to radioisotopes, drugs, toxins, enzymes and biosensor surfaces.
重组抗体及其片段目前占所有正在进行临床试验的生物蛋白的30%以上，最近这一成果达到高潮，首个工程化癌症治疗抗体获得了美国食品药品监督管理局（FDA）的批准。其他成功应用包括有效增强用于癌症治疗的人体免疫反应，以及减少移植和抗体治疗后不必要的免疫排斥反应。在这些新型工程抗体的设计、筛选和生产方法方面已经取得了重要进展。创新的筛选方法使得催化抗体和高亲和力病毒特异性抗体得以分离，后者能够将病毒重新导向基因治疗应用。在众多实际应用中，重组抗体片段已与放射性同位素、药物、毒素、酶和生物传感器表面融合。
